期刊文献+

阿托伐他汀钙对冠心病心力衰竭患者心功能的影响 被引量:10

The Effect of Cardiac Function of Atorvastatin Calcium in Patients with CHF
下载PDF
导出
摘要 目的探讨阿托伐他汀钙对冠心病充血性心力衰竭(CHF)患者心功能的影响。方法 79例冠心病心力衰竭患者为2组,对照组按心衰治疗常规进行治疗,实验组加用阿托伐他汀钙治疗。治疗6个月后,比较两组患者心功能变化。结果实验组患者治疗6个月后左心射血分数(LVEF)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)改善较对照组明显,差异有统计学意义(t=8.3、5.3、4.0,P<0.05)。实验组心功能改善率(80.0%)明显高于对照组(53.9%),差异有统计学意义(χ2=6.12,P<0.05)。结论阿托伐他汀钙应用于冠心病心力衰竭患者,可明显改善患者的心功能。 Objective To explore the effect of cardiac function of atorvastatin calcium in patients with CHF.Methods Divided 79 cases of patients with CHF into two groups randomly,while control group received conventional treatment and experimental group received atorvastatin calcium else.After treated six months,compared the cardiac function of two groups.Results After treated six months,LVEF,LVEDD and LVESD of experimental group were improved more significanter than control group(t=8.3,5.3,4.0,P0.05).Improve rate of cardiac function of experimental group(80%) was higher than control group(53.9%),and a significant difference was observed(χ2=6.12,P0.05).Conclusion For patients with CHF,atorvastatin calcium can significantly improve the cardiac function.
作者 王辉华
出处 《中国医药指南》 2012年第35期425-426,共2页 Guide of China Medicine
关键词 阿托伐他汀钙 冠心病 心力衰竭 心功能 Atorvastatin calcium Coronary heart disease Congestive heart failure Cardiac function
  • 相关文献

参考文献7

二级参考文献24

  • 1李爱民,黄岚,宋耀明,覃军,何作云,祝善俊.慢性心力衰竭患者血清MCP-1变化及氯沙坦的干预效应[J].重庆医学,2005,34(9):1359-1360. 被引量:2
  • 2Kohler F, Winkler S, Schieber M, et al. Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study [J].Circulation, 2011 ; 123 ( 17 ) : 1873-80. 被引量:1
  • 3Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure :rationale for preventive strategies and comprehensive dis- ease management [J].Am Heart J, 1997 ; 133 : 703 -12. 被引量:1
  • 4Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of chronic heart failure[J].Eur Heart J.1997:18:208-25. 被引量:1
  • 5Davidson MH, Abate N, Ballantyne CM, et aL Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/ apo-A-I, or C-reactive protein[J]. J Clin Lipidol,2008;2(6) :43646. 被引量:1
  • 6Vredevoe DL, Woo MA, Doering LV ,et al. Skin test anergy in advanced chronic heart failure secondary to either ischemic or idiopathic dilated car- diomyopathy [J]. Am J Cardiol, 1998 ; 82 : 323-8. 被引量:1
  • 7Horwich TB, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure [J]. J Card Fail, 2002 ;8:216-24. 被引量:1
  • 8Lizak MK, Zakliczynski M, Jarosz A,et al. High-density lipoprotein cho- lesterol levels and risk of death in chronic heart failure patients referred for heart transplant evaluation[J]. J Heart Lung Transplant, 2010; 29(3) :386-7. 被引量:1
  • 9Rauchhaus M, Clark AL, Doehner W, et al. The relationship betweencholesterol and survival in patients with chronic heart failure [J].J Am Coil Cardiol,2003 ;42( 11 ) :1933-40. 被引量:1
  • 10Netea MG, Demacker PNM, Kullberg B J, et al. Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and se- vere gram-negative infections[J].Clin Invest, 1996 ;97 ( 6 ) : 1366-72. 被引量:1

共引文献125

同被引文献89

引证文献10

二级引证文献94

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部